CA3029875C - Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same - Google Patents
Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same Download PDFInfo
- Publication number
- CA3029875C CA3029875C CA3029875A CA3029875A CA3029875C CA 3029875 C CA3029875 C CA 3029875C CA 3029875 A CA3029875 A CA 3029875A CA 3029875 A CA3029875 A CA 3029875A CA 3029875 C CA3029875 C CA 3029875C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- independently
- tumors
- pi3k
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359001P | 2016-07-06 | 2016-07-06 | |
| US62/359,001 | 2016-07-06 | ||
| US201762454163P | 2017-02-03 | 2017-02-03 | |
| US62/454,163 | 2017-02-03 | ||
| PCT/US2017/040866 WO2018009638A1 (en) | 2016-07-06 | 2017-07-06 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3029875A1 CA3029875A1 (en) | 2018-01-11 |
| CA3029875C true CA3029875C (en) | 2023-12-19 |
Family
ID=59363277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3029875A Active CA3029875C (en) | 2016-07-06 | 2017-07-06 | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10919877B2 (enExample) |
| EP (2) | EP4086250B1 (enExample) |
| JP (2) | JP2019519593A (enExample) |
| CN (1) | CN109563088B (enExample) |
| AU (2) | AU2017291838B2 (enExample) |
| CA (1) | CA3029875C (enExample) |
| ES (2) | ES3002745T3 (enExample) |
| WO (1) | WO2018009638A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311624B2 (en) | 2017-08-11 | 2022-04-26 | The Regents Of The University Of Michigan | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds |
| CN112143700B (zh) * | 2019-06-26 | 2024-07-19 | 上海细胞治疗集团股份有限公司 | 制备过表达外源基因的免疫效应细胞的方法 |
| CN117396470A (zh) * | 2021-04-09 | 2024-01-12 | 巴塞尔大学 | 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物 |
| JP2024516361A (ja) * | 2021-04-09 | 2024-04-15 | ウニヴェアズィテート バーゼル | Ｐｉ３ｋの可逆的および不可逆的共有結合性阻害剤としてのトリアジン誘導体 |
| WO2023170107A1 (en) | 2022-03-07 | 2023-09-14 | Centre Hospitalier Universitaire Vaudois (Chuv) | Pi3k/akt/mtor inhibitor for improving the cellular uptake of a radiopharmaceutical |
| JP2023180347A (ja) * | 2022-06-09 | 2023-12-21 | 国立大学法人金沢大学 | ハイブリッド型化合物又はその塩 |
| CN116617227A (zh) * | 2023-06-09 | 2023-08-22 | 苏州大学 | 三氟噻吨在治疗脑血管疾病中的应用 |
| WO2025072796A1 (en) * | 2023-09-27 | 2025-04-03 | Totus Medicines Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA197701A (en) | 1920-03-02 | Mcgoldrick Timothy | Arm cushion for crutches | |
| CA85878A (en) | 1903-08-19 | 1904-03-08 | George W. Peyton | Carpenter's gauge |
| US5608110A (en) | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2008032162A1 (en) | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| US8569378B2 (en) | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| EP2276750A2 (en) | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| WO2009155121A2 (en) * | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| EP2143819A1 (de) | 2008-07-11 | 2010-01-13 | Siemens Aktiengesellschaft | Beschichtungsverfahren und Korrosionsschutzbeschichtung für Turbinen-Komponenten |
| TW201038567A (en) | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| US20110166191A1 (en) | 2010-01-07 | 2011-07-07 | Shijun Zhang | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer |
| GB201007227D0 (en) | 2010-04-30 | 2010-06-16 | Univ Basel | Piperazinotriazines |
| EP2604601B1 (en) * | 2010-08-10 | 2016-02-24 | Astellas Pharma Inc. | Hetero ring compound |
| EP2640367A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| US9284334B2 (en) * | 2011-05-19 | 2016-03-15 | Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii | Macrocyclic compounds as protein kinase inhibitors |
| EP2781520B1 (en) | 2011-11-17 | 2016-05-04 | Xuanzhu Pharma Co., Ltd. | Three-ring pi3k and/or mtor inhibitor |
| EP2968345B1 (en) | 2013-03-13 | 2017-12-13 | The Regents of The University of Michigan | Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases |
| KR20150143672A (ko) * | 2013-04-12 | 2015-12-23 | 아사나 바이오사이언시스 엘엘씨 | Ras/raf/mek/erk 및 pi3k/akt/pten/mtor 경로의 이중 억제제로서의 퀴나졸린 및 아자퀴나졸린 |
| CN105130960B (zh) * | 2015-07-31 | 2018-07-06 | 沈阳药科大学 | 1,3,5-三嗪类衍生物及其应用 |
-
2017
- 2017-07-06 JP JP2018568930A patent/JP2019519593A/ja active Pending
- 2017-07-06 US US16/313,923 patent/US10919877B2/en active Active
- 2017-07-06 EP EP22179630.3A patent/EP4086250B1/en active Active
- 2017-07-06 ES ES22179630T patent/ES3002745T3/es active Active
- 2017-07-06 EP EP17740578.4A patent/EP3481822B1/en active Active
- 2017-07-06 ES ES17740578T patent/ES2922898T3/es active Active
- 2017-07-06 CN CN201780049835.8A patent/CN109563088B/zh active Active
- 2017-07-06 WO PCT/US2017/040866 patent/WO2018009638A1/en not_active Ceased
- 2017-07-06 AU AU2017291838A patent/AU2017291838B2/en active Active
- 2017-07-06 CA CA3029875A patent/CA3029875C/en active Active
-
2021
- 2021-04-28 AU AU2021202619A patent/AU2021202619B2/en active Active
- 2021-11-24 JP JP2021190205A patent/JP7475062B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3029875A1 (en) | 2018-01-11 |
| US20190224207A1 (en) | 2019-07-25 |
| AU2021202619A1 (en) | 2021-05-27 |
| EP4086250A2 (en) | 2022-11-09 |
| ES2922898T3 (es) | 2022-09-21 |
| AU2017291838A1 (en) | 2019-01-17 |
| ES3002745T3 (en) | 2025-03-07 |
| CN109563088A (zh) | 2019-04-02 |
| CN109563088B (zh) | 2022-10-11 |
| AU2017291838B2 (en) | 2021-01-28 |
| EP4086250B1 (en) | 2024-12-11 |
| EP3481822A1 (en) | 2019-05-15 |
| EP4086250C0 (en) | 2024-12-11 |
| JP2022019812A (ja) | 2022-01-27 |
| EP3481822B1 (en) | 2022-06-22 |
| JP2019519593A (ja) | 2019-07-11 |
| JP7475062B2 (ja) | 2024-04-26 |
| US10919877B2 (en) | 2021-02-16 |
| WO2018009638A1 (en) | 2018-01-11 |
| AU2021202619B2 (en) | 2022-03-10 |
| EP4086250A3 (en) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202619B2 (en) | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | |
| EP2968345B1 (en) | Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases | |
| US20110319362A1 (en) | Stat3 ligands and therapeutic uses thereof | |
| JP2013503837A (ja) | ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法 | |
| JP6637890B2 (ja) | ベンズアミド及びニコチンアミド化合物及びこれを使用する方法 | |
| JP2024525740A (ja) | 小分子サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）およびｉｋｚｆ２（ｈｅｌｉｏｓ）分解剤並びにその使用方法 | |
| CA2882157A1 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| CN106459011B (zh) | 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 | |
| EP4460306A2 (en) | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) | |
| US20230226196A1 (en) | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use | |
| WO2025207686A2 (en) | Small molecule modified boron containing compounds and methods of use thereof | |
| JP2024538132A (ja) | Ｄｏｔ１ｌ分解のための小分子およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |
|
| EEER | Examination request |
Effective date: 20220210 |